Publications by authors named "David Valcarcel"

Claim this Profile
I
Ixazomib decreases the risk of chronic graft-versus-host disease: identification of cGVHD biomarkers.
Teresa Caballero-Velázquez, Javier Delgado Serrano, Lucía López-Corral, Christelle Ferra-Coll, Clara Beatriz García-Calderón

Blood Adv· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Stroke, idiopathic thrombocytopenic purpura and avatrombopag: two cases of coincident events.
Bernat Boy, Gloria Iacoboni, David Valcárcel, Carlos Molina, Marc Rodrigo-Gisbert

Neurol Sci· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pivotal results of SELECT-MDS-1 phase 3 study of tamibarotene with azacitidine in newly diagnosed higher-risk MDS.
Amy E DeZern, Sylvain Thepot, Stephane de Botton, Andrea Patriarca, Dries Deeren, David Valcarcel

Blood Adv· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Myelodysplastic neoplasms with ring sideroblasts without SF3B1 mutations in adults: enrichment of germline variants in congenital sideroblastic anemia genes.
Sandra Novoa-Jáuregui, Sandra Huber, Maria Gabarrós-Subirà, Tzu Hua Chen-Liang, Sara Torres-Esquius

Leukemia· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-Term Transfusion Independence with Luspatercept Versus Epoetin Alfa in Erythropoiesis-Stimulating Agent-Naive, Lower-Risk Myelodysplastic Syndromes in the COMMANDS Trial.
Guillermo Garcia-Manero, Valeria Santini, Amer M Zeidan, Rami S Komrokji, Veronika Pozharskaya

Adv Ther· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 1, first-in-human, dose-escalation study of JNJ-74856665 (dihydroorotate dehydrogenase inhibitor) alone or in combination in patients with AML or MDS.
Emma Searle, Thomas Cluzeau, Jenny O'Nions, Christian Recher, Emmanuel Gyan

Br J Haematol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Interplay of leucocyte-platelet complexes and clinical response to eltrombopag in immune thrombocytopenia patients.
Rubén Osuna-Gómez, Carlos Zamora, Silvana Novelli, Francesc Garcia-Pallarols, Yva Rodriguez, David Valcarcel

Br J Haematol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Caplacizumab treatment in elderly patients with iTTP: Experience from the Spanish TTP Registry.
Inés Gómez-Seguí, Joan Cid, Miquel Lozano, Maria Eva Mingot-Castellano, Cristina Pascual-Izquierdo, David Valcarcel

Hemasphere· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hypomethylating agents plus venetoclax for high-risk MDS and CMML as bridge therapy to transplant: a GESMD study.
Ines Zugasti, Monica Lopez-Guerra, Sandra Castaño-Díez, Daniel Esteban, Alejandro Avendaño

Exp Hematol Oncol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Ruxolitinib in acute and chronic graft-versus-host disease: real life long-term experience in a multi-center study for adult and pediatric patients, on behalf of the GETH-TC.
Virginia Escamilla-Gómez, Valentín García Gutiérrez, Patricia Alcalde-Mellado, Beatriz Astibia-Mahillo, Anabelle Chinea-Rodriguez

Bone Marrow Transplant· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Proactive assessment of patient reported outcomes in ovarian cancer studies: a systematic review and call for action in future studies.
Ainhoa Madariaga, Rodrigo Sánchez-Bayona, Lawrence Kasherman, Jose Manuel Estrada-Lorenzo, Luis Manso, David Valcarcel

Int J Gynecol Cancer· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Post-transplant cyclophosphamide compared to sirolimus/tacrolimus in reduced intensity conditioning transplants for patients with lymphoid malignancies.
Maria Laura Fox, Irene García-Cadenas, Victor Navarro, Ariadna Pérez Martínez, Meriem Kara

Bone Marrow Transplant· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Influence of TP53 gene mutations and their allelic status in myelodysplastic syndromes with isolated 5q deletion.
Maria Julia Montoro, Laura Palomo, Claudia Haferlach, Pamela Acha, Onyee Chan

Blood· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): primary analysis of a phase 3, open-label, randomised, controlled trial.
Matteo Giovanni Della Porta, Guillermo Garcia-Manero, Valeria Santini, Amer M Zeidan, Rami S Komrokji

Lancet Haematol· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Germline assessment for alloHSCT candidates over 50 years: A 'Fast-Track' screening in myeloid neoplasms.
Sara Torres-Esquius, Francisco Beas, Tzu Hua Chen-Liang, Helena Pomares, Marta Santiago

Br J Haematol· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: Cryopreservation of unrelated donor hematopoietic stem cells: the right answer for transplantations during the COVID-19 pandemic?
Jesus Fernandez-Sojo, Carmen Azqueta, Elena Valdivia, Lluis Martorell, Laura Medina-Boronat

Bone Marrow Transplant· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Single-cell transcriptional profile of CD34+ hematopoietic progenitor cells from del(5q) myelodysplastic syndromes and impact of lenalidomide.
Guillermo Serrano, Nerea Berastegui, Aintzane Díaz-Mazkiaran, Paula García-Olloqui, Carmen Rodriguez-Res, David Valcarcel

Nat Commun· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
DNA methylation profiling of myelodysplastic syndromes and clinical response to azacitidine: A multicentre retrospective study.
Aleix Noguera-Castells, Ignacio Campillo-Marcos, Veronica Davalos, Carlos A García-Prieto, David Valcárcel

Br J Haematol· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immune-monitoring of myelodysplastic neoplasms: Recommendations from the i4MDS consortium.
Cristina A Tentori, Lin P Zhao, Benedetta Tinterri, Kathryn E Strange, Katharina Zoldan, David Valcarcel

Hemasphere· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Validation of the Artificial Intelligence Prognostic Scoring System for Myelodysplastic Syndromes in chronic myelomonocytic leukaemia: A novel approach for improved risk stratification.
Adrian Mosquera Orgueira, Manuel Mateo Perez Encinas, Nicolas Diaz Varela, Yu-Hung Wang, Elvira Mora

Br J Haematol· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Ofatumumab as part of reduced intensity conditioning in high risk B-cell lymphoma patients: final long-term analysis from a prospective multicenter Phase-II Trial.
Mónica Cabrero, Lucia López-Corral, Isidro Jarque, Fátima de la Cruz-Vicente, Estefanía Pérez-López

Bone Marrow Transplant· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Single-cell Multiomics Analysis of Myelodysplastic Syndromes and Clinical Response to Hypomethylating Therapy.
Ignacio Campillo-Marcos, Marta Casado-Pelaez, Veronica Davalos, Gerardo Ferrer, Caterina Mata

Cancer Res Commun· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Imetelstat in patients with lower-risk myelodysplastic syndromes who have relapsed or are refractory to erythropoiesis-stimulating agents (IMerge): a multinational, randomised, double-blind, placebo-controlled, phase 3 trial.
Uwe Platzbecker, Valeria Santini, Pierre Fenaux, Mikkael A Sekeres, Michael R Savona

Lancet· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis